Latest Financial Health News

Gale Pacific has reported a stronger-than-expected first half for FY26, delivering EBITDA of $5.7 million and positive operating cash flow despite challenging market conditions. Strategic restructuring and cost efficiencies are driving improved financial health.

ASX Limited has updated its FY26 expense growth guidance upwards, reflecting increased investments in risk management and technology modernisation alongside ASIC Inquiry-related costs, while reporting strong unaudited 1H26 revenue growth.

SenSen Networks has reported record cash receipts for the first half of FY26, driven by strong sales momentum in North America and Australia, alongside innovative product deployments.

Metro Mining delivered a record 6.2 million wet metric tonnes in 2025 shipments, supported by a strong cash position and nearing completion of legacy contracts. The company is poised for expanded production and improved margins in 2026 following operational and leadership changes.

Algorae Pharmaceuticals has advanced its AI drug discovery capabilities with the launch of AlgoraeOS v2 and secured key commercial partnerships, including a $3 million debt facility to support expansion in Australia and New Zealand.

Bioxyne Limited has reported a record $17.2 million in quarterly revenue, driven by strong growth in its cannabis and psychedelics segments, alongside strategic international expansions including a Frankfurt dual listing and new manufacturing agreements.

Scalare Partners reported a remarkable 231% revenue increase in Q2 FY26, driven by full integration of recent acquisitions and new ecosystem initiatives. The company also turned operating cashflow positive, signalling strong momentum ahead.

Ampol Limited reports a robust fourth quarter Lytton Refiner Margin of US$15.14 per barrel, underpinning a strong preliminary FY25 earnings update with an expected EBIT of approximately $945 million.

Tetratherix Limited (ASX, TTX) reports significant progress in clinical trials, strategic partnerships, and manufacturing capacity, positioning itself for near-term commercialisation and sustained innovation.

Clever Culture Systems has expanded its APAS Independence installed base to 27 instruments globally and surpassed $1 million in annual recurring revenue, underpinned by strong sales momentum and customer validation.

Firebrick Pharma has commenced commercial manufacturing and export of its new Nasodine Throat Spray, marking a significant step in its international expansion. The company also reported a 15% increase in cash sales and reduced operating costs, signalling improving financial health.

Strategic Elements Ltd reports steady progress in its cutting-edge ventures across automation, AI, and material science, supported by a strong cash position and government-backed innovation incentives.